SavedAdd your journal

Journals / Haseki Tıp Bülteni / 2015 / Cilt: 53 - Sayı: 4

Aritmojenik Sağ Ventrikül Kardiyomyopatisi/Displazisi olan Hastalarda Ortalama Trombosit Hacmi

Mean Platelet Volume in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia

İBRAHİM ALTUN
Fatih AKIN
Murat BİTEKER
Nuri KÖSE
Göksel GÜZ
Fahrettin ÖZ
İmran ÖNÜR
Ahmet Kaya BİLGE
Kamil ADALET
Pages
303–307
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion:­Our results suggest that patients with ARVC/D have increased platelet activation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim:­ Arrhythmogenic right ventricular cardiomyopathy or dysplasia (ARVC/D) is characterized by the gradual replacement of the right ventricular myocardium with fibrous and adipose tissue and can cause ventricular tachyarrhythmia in young patients.
📊
Key Findings & Data:Methods:­ Twenty-nine patients (23 men, age: 38.0±13.1 years) with ARVC/D and forty-one healthy subjects (30 men, age: 39.3±11.8 years) were studied.
💡
Conclusion & Impact:Conclusion:­Our results suggest that patients with ARVC/D have increased platelet activation.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim:­ Arrhythmogenic right ventricular cardiomyopathy or dysplasia (ARVC/D) is characterized by the gradual replacement of the right ventricular myocardium with fibrous and adipose tissue and can cause ventricular tachyarrhythmia in young patients. Mean platelet volume (MPV) is reported to be an easily measurable marker reflecting platelet activation and plays an important role in the pathophysiology of cardiovascular disorders. In this study, we aimed to assess MPV in patients with ARVC/D. Methods:­ Twenty-nine patients (23 men, age: 38.0±13.1 years) with ARVC/D and forty-one healthy subjects (30 men, age: 39.3±11.8 years) were studied. Plasma MPV was measured in ARVC/D patients and control subjects. Results:­ The MPV was higher in patients with ARVC/D when compared with the control group (9.87±1.0 vs. 8.2±1.1 fl, p<0.01). To investigate any possible connection between MPV and clinical presentation of ARVC/D, ARVC/D patients were separated into two groups according to the presence of syncope and sudden cardiac death (SCD). MPV was higher in ARVC/D patients with SCD compared to those without cardiac arrest, but the difference was not statistically significant. Conclusion:­Our results suggest that patients with ARVC/D have increased platelet activation.

Özet

Amaç:­Aritmojenik sağ ventrikül kardiyomyopatisi veya displazisi (ARVC/D) kalp kasının genetik bir hastalığıdır. Sağ ventrikül myokardında fibroz ve yağ dokususu artışı ile karakterize olan bu hastalık gençlerde ventriküler taşikardiye yol açabilmektedir. Ortalama trombosit hacmi, kolayca ölçülebilen bir trombosit fonksiyon göstergesi olup kardiyovasküler hastalıkların patofizyolojisinde hastalarda ortalama trombombosit hacmi ile ilgili bir çalışma bulunmamaktadır. Biz bu çalışmada ARVC/D hastalarında ortalama trombosit hacmini değerlendirmeyi amaçladık.Yöntemler:­Çalışmaya 29 ARVC/D hastası (23 erkek, ortalama yaş: 38,0±13,1 yıl) ve 41 sağlıklı (30 erkek, ortalama yaş: 39,3±11,8 yıl) kişi alındı. Hasta ve kontrol grubu yaş ve cinsiyet bakımından benzer idi. Ortalama trombosit hacmi (OTH) düzeyleri her iki grupta da ölçüldü.Bulgular:­ OTH kontrol grubu ile kıyaslandığında ARVC/D hastalarında anlamlı olarak yüksek saptandı (9,87±1,0 vs. 8,2±1,1 fl, p<0,01). OTH'nin, ARVC/D hastalarının klinik prezentasyonu ile olan ilişkisini değerlendirmek için ARVC/D hastaların, bayılma ve ani ölümle başvuranlar diye iki alt gruba ayrıldı. Ani ölümle başvuranlarda OTH yüksek olmakla birlikte istatistiksel olarak anlamlı saptanmadı.Sonuç:­ ARVC/D hastalarında OTH değerleri anlamlı olarak yüksek saptandı. Bu sonuçlarımız ARVC/D hastalarında trombosit fonksiyonlarının artmış olduğunu göstermektedir.

🔖

Cite This Article

ALTUN, İ., AKIN, F., BİTEKER, M., KÖSE, N., GÜZ, G., ÖZ, F., ÖNÜR, İ., BİLGE, A. K., ADALET, K. (2015). Aritmojenik Sağ Ventrikül Kardiyomyopatisi/Displazisi olan Hastalarda Ortalama Trombosit Hacmi. Haseki Tıp Bülteni, Cilt: 53 - Sayı: 4, 303–307. https://ajindex.com/articles/215286

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Marcus FI, Fontaine GH, Guiraudon G, et al. Right ventricular dysplasia: a report of 24 adult cases. Circulation 1982; 65:384-98.
  2. McKoy G, Protonotarios N, Crosby A, et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet 2000;355:2119-24.
  3. Norgett EE, Hatsell SJ, Carvajal-Huerta L, et al. Recessive mutation in desmoplakin disrupts desmoplakin- intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. Hum Mol Genet 2000;9:2761-6.
  4. Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med 1988;318:129-33.
  5. Ananthasubramaniam K, Khaja F. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: review for the clinician. Prog Cardiovasc Dis 1998;41:237-46.
  6. Park Y, Schoene N, Haris W. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets 2002;13:301-6.
  7. Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP. Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost 2003;9:177-90.
  8. Jung DH, Lee HR, Lee YJ, Kim JK, Park BJ, Shim JY. The association between coronary artery calcification and mean platelet volume in the general population. Platelets 2011;22:567-71.
  9. Van der Loo B, Martin JF. Megakaryocytes and platelets in vascular disease. Baillieres Clin Haematol 1997;10:109-23. Martin JF. Platelet heterogeneity in vascular disease. In: Martin JF, Trowbridge EA, editors. Platelet heterogeneity: Biology and Pathology. London, Springer; 1990. p. 205-26.
  10. McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J 1994;71:215-8.
  11. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Eur Heart J 2010;31:806-14.
  12. Ozben B, Altun I, Sabri Hancer V, et al. Angiotensin- converting enzyme gene polymorphism in arrhythmogenic right ventricular dysplasia: is DD genotype helpful in predicting syncope risk? J Renin Angiotensin Aldosterone Syst 2008;9:215-20.
  13. Campuzano O, Alcalde M, Iglesias A, et